$Editas Medicine(EDIT.US)$ NEWS Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
Despite Editas Medicine's stock price surge, its P/S ratio remains modest due to inferior revenue forecasts. Without revenue improvement, the P/S ratio will continue to limit the share price.
Analysts are divided on Editas Medicine's performance, with some optimistic and others pessimistic. The projected increase in losses next year is worrisome, despite the rise in revenue estimates. The company's revenue growth is anticipated to lag behind the broader industry, posing a potential downside.
Increased forecast losses for Editas Medicine indicate potential issues, with revenues expected to grow slower than the market. The drastic downgrade to this year's forecasts raises caution towards the company's future performance.
Editas Medicine's share price bounce is expected after a significant drop, but the underlying business needs to justify a higher price. The weak revenue result is concerning, and the falling share price is likened to 'trying to catch a falling knife'. The recent share price recovery is viewed skeptically.
Despite recent gains in share price, the company's weak revenue trend and non-profitable status can question future performance. The stock returns also lag behind the market, suggesting potential growth issues.
Citi analyst Samantha Semenkow anticipates FDA experts' positive stance on exa-cel, similar to Zynteglo and Skysona last year. She suggests Beam shares could increase 10%-30% following favorable FDA commentary and sees buoyant future for Editas Medicine on expected AdCom and EDIT-301 data readout.
Pre-Market Stock Movers Gapping up $耐克(NKE.US)$ (The sneaker behemoth added nearly 10% in premarket trading after a mixed earnings report. The company reported 94 cents per share and $12.94 billion in revenue, while analysts polled by LSEG forecast 75 cents and $12.98 million, respectively. Nike also reiterated mid-single digit full-year revenue growth guidance.) $Uranium Energy(UEC.US)$ (The uranium miner added 2% after the company...
Editas Medicine股票讨论区
NEWS
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
Gapping up
$耐克(NKE.US)$
(The sneaker behemoth added nearly 10% in premarket trading after a mixed earnings report. The company reported 94 cents per share and $12.94 billion in revenue, while analysts polled by LSEG forecast 75 cents and $12.98 million, respectively. Nike also reiterated mid-single digit full-year revenue growth guidance.)
$Uranium Energy(UEC.US)$
(The uranium miner added 2% after the company...
暂无评论